Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model

28 Aug 2017

Abstract excerpt

ABSTRACT Cefiderocol (S-649266) is a novel siderophore cephalosporin with potent in vitro activity against clinically encountered multidrug-resistant (MDR) Gram-negative isolates; however, its spectrum of antibacterial activity against these difficult-to-treat isolates remains to be fully explored in vivo . Here, we evaluated the efficacy of cefiderocol humanized exposures in a neutropenic murine thigh model to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Bacterial Identification and Susceptibility Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28848004
DOI: 10.1128/aac.01022-17

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection ModelPMID 28848004Read ↗

Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosaSemantic proximity Read ↗

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance MechanismsSemantic proximity Read ↗

Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.Semantic proximity Read ↗

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance ProgramSemantic proximity Read ↗

Real‑world effectiveness and safety of cefiderocol in critically ill patients with MDR Gram‑negative infections: Results from a retrospective studySemantic proximity Read ↗

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant PathogensSemantic proximity Read ↗

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging DataSemantic proximity Read ↗

Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE StudySemantic proximity Read ↗

Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.Semantic proximity Read ↗

In Vivo Efficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae IsolatesSemantic proximity Read ↗

Cefiderocol: a novel siderophore cephalosporinSemantic proximity Read ↗

Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-IDSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.